Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer

Molecular imaging with ??Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer. According to new research published in the October issue of The Journal of Nuclear Medicine, ??Ga-HER2 PET/CT can detect changes in HER2-positive breast cancer after only two cycles of neoadjuvant treatment, giving physicians information that could support earlier discussions about subsequent treatment and surgical planning. Limits of current response monitoring HER2-positive tumors, which represent 20% to 25% of all breast cancer cases, are aggressive and associated with poorer outcomes. Neoadjuvant therapy is often given to patients before…